Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

Sarepta Therapeutics (SRPT) experienced a tumultuous 2025, with its stock plummeting over 85% and losing nearly $10 billion in market capitalization following multiple patient deaths linked to its FDA-approved Duchenne muscular dystrophy gene therapy, ELEVIDYS, which prompted an initial FDA sales halt. However, a subsequent FDA reversal, allowing sales to the profitable ambulatory patient segment (70-85% of ELEVIDYS users), sparked a 50% stock rebound. While some analysts now project significant upside, citing the stock's undervaluation at 1.2x forward P/S versus an industry median of 4.3x, others remain cautious due to ongoing risks of further adverse events, potential renewed FDA intervention, and emerging competitive therapies.

Analysis

Sarepta Therapeutics (SRPT) presents a high-stakes, event-driven investment case following extreme volatility in 2025. The company's stock plummeted over 85% after its sole FDA-approved gene therapy for Duchenne muscular dystrophy (DMD), ELEVIDYS, was linked to multiple patient deaths, leading to a temporary FDA-requested sales halt. A subsequent partial reversal by the FDA, which concluded one death was likely unrelated to the drug, has allowed Sarepta to resume sales to its core ambulatory patient segment, which accounts for 70-85% of users and is sufficient for profitability. This FDA reversal catalyzed a 50% rebound in the stock price as of August 11. The core bull thesis rests on a compelling valuation argument: the company's market capitalization has collapsed by nearly $10 billion to $1.75 billion, resulting in a forward price-to-sales ratio of just 1.2x, a significant discount to the biotech industry median of 4.3x. This is supported by the fact that 54% of Sarepta's fiscal 2024 revenue came from products other than ELEVIDYS, providing some revenue diversification. However, this is countered by severe, binary risks. The foremost risk is another patient death definitively linked to ELEVIDYS, which would likely trigger a renewed and potentially permanent sales halt. Furthermore, long-term competitive pressure is emerging from Solid Biosciences' SGT-003, which has shown strong early-stage efficacy and a design that may mitigate the liver-related safety concerns affecting ELEVIDYS. The wide dispersion in analyst price targets, from $13 to north of $50, encapsulates this deep uncertainty.

Key Decisions for Investors

• Investors must closely monitor for any new adverse event reports or regulatory updates from the FDA concerning ELEVIDYS, as this remains the primary catalyst for short-term stock volatility.
• For investors with a high-risk tolerance, the current forward P/S multiple of 1.2x presents a deep value opportunity, but any position should be sized to withstand the significant downside potential highlighted by bear-case price targets of $13-$15.
• Long-term investors should track the clinical trial progress of competitors, particularly Solid Biosciences' SGT-003, as a successful trial and potential approval would materially erode Sarepta's market share and long-term growth outlook.
• Consider the resumption of sales to the profitable ambulatory patient segment as a key operational positive, but weigh this against the overhang of potential future clinical setbacks before adjusting positions.